AT-104 is an investigational, novel phosphatidylinositol 3-kinase (PI3K) inhibitor being developed for the treatment of rare, high unmet need oncology indications, including T-Cell Acute Lymphoblastic Leukemia (T-ALL), Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). AT-104 has been granted Pediatric Rare Disease designation for T-ALL.

AT-007-1005 Clinical Study

Please fill out the form below to view information about AT-007, e.g. a list of contraindicated medications.